Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Oct 12, 2015
New US patent covering use of trofinetide for Rett syndrome
Sep 29, 2015
Neuren provides update on Fragile X and INTREPID trials
Aug 25, 2015
Half Yearly Report and Accounts 30 June 2015
Aug 14, 2015
trofinetide confirmed as INN for Neuren's NNZ-2566
Aug 13, 2015
Neuren confirms orphan drug designations in Europe
Jul 31, 2015
Investor presentation, 31 July 2015
Jul 30, 2015
Appendix 4C - quarterly
Jul 29, 2015
Neuren reports progress in orphan drug programs
Jun 01, 2015
Appendix 3B
May 07, 2015
Appendix 3B
Previous
1
2
3
4
Next